Study to determine effectiveness and safety of zoledronic acid and whether it has a pharmaco-economic impact in prostate cancer with bone metastasis.

Inclusion Criteria:

• Aged ≥18 years.
• Written informed consent.
• With histologically-proven prostate carcinoma.
• ECOG performance status ≤ 2
• Life expectancy > 12 months
• Current or previously documented diagnosis of at least 1 bone metastasis due to prostate cancer (patient could be hormono naif, Hormono sensible or hormono refractory)
• Patients with partners of childbearing potential should use a barrier method of contraception throughout the study.

Exclusion Criteria:

• ECOG performans status >3
• Prior treatment with bisphosphonates IV within the last 3 month to the study
• Renal insufficiency (serum creatinine > 265 micromol/L or > 3.0 mg/dL)
• Liver function tests > 2.5 ULN
• Patients with another nonmalignant disease which would confuse the evaluation of primary endpoints or prevent the patient from complying with the protocol.
• History of concomitant disease with influence on bone metabolism such as Paget's disease or primary hyperparathyroidism
• Disabling or non controlled concomitant disease likely to alter the quality of life
• Patient unable to fill in a questionnaire: senile dementia, psychiatric or neurological disease, illiterate or partially sighted patient
• Known hypersensitivity to zoledronic acid or other bisphosphonates

Other protocol-defined inclusion / exclusion criteria may apply.